Multi-center clincal study of administration arginine acetate on improvement immune function in trauma, burn and surgical patients

Randomized double-blind controlled trial of administration arginine acetate on maintenacnce immune fuction and improvement prognosis in trauma, burn and surgical patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001717

Enrollment

Unknown

Registered

2011-11-16

Start date

2004-12-10

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Trauma, Burn, tumor

Interventions

2:administration arginine acetate

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. 18-65 years old patients, male or female; 2. Trauma(ISS>16), Burn(TBSA:25-70%) and Postoperation of gastrointestinal tumor patients; 3. Not use other immune drugs; 4. No serious liver, kidney, heart, vascular and hematopoietic system diseases.

Exclusion criteria

Exclusion criteria: 1. Severe diseases in heart, liver, kidney or hematopoietic system before admission; 2. Severe asthma and chronic respiratory diseases before admission; 3. Used other immune drugs; 4. Pregnant or lactating women; 5. Mental diseases, no self-control capacity or no articulate.

Design outcomes

Primary

Measure	Time frame
NK cell population;CD4/CD8 ratio;Contents of plasma immunoglobulin;Incidence of visceral complications;sepsis incidence;hospital-stay period;wound healing time;	—

Secondary

Measure	Time frame
Contents of plasma IL-2;Contents of plasma IL-4;Contents of plasma prealbumin;Contents of plasma transferrin;	—

Countries

China

Contacts

Public ContactXi Peng

pxlrmm@163.com+86 023 68754149-8056

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026